{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:45:06Z","timestamp":1788209106641,"version":"build-2803163510"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2024-0373_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate measurements of renin and aldosterone levels play an important role in primary aldosteronism screening, which is of great importance in the management and categorization of hypertension. The objective of this study\u00a0is to investigate the current status of plasma renin and aldosterone measurements in China, which is achieved by analyzing the results of 526 clinical laboratories nationwide for three pooled fresh plasma samples derived from more than 2,000 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-0373_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Renin and aldosterone in three pooled plasma samples were measured four times in 526 laboratories employing various measurement systems. The inter- and intra-laboratory %CV were calculated and compared. To determine the source of the substantial inter-laboratory %CV,\u00a0laboratories were categorized according to the measurement systems they are using, and both the inter- and intra-measurement-system %CV were calculated and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-0373_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regarding renin, the majority of laboratories use four primary commercial immunoassays. However, for aldosterone, in addition to commercial immunoassays, laboratory-developed liquid chromatography-tandem mass spectrometry (LC-MS) methods are also used by laboratories. The median values of intra-laboratory %CVs, intra-measurement-system %CVs, inter-laboratory %CVs, and inter-measurement systems %CVs varied between 1.6 and 2.6\u202f%, 4.6 and 14.9\u202f%, 8.3 and 25.7\u202f%, and 10.0 and 34.4\u202f% for renin, respectively. For aldosterone, these values ranged from 1.4 to 2.2\u202f%, 2.5\u201314.7\u202f%, 9.9\u201331.0\u202f%, and 10.0\u201335.5\u202f%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-0373_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The precision within laboratories and measurement systems for plasma renin and aldosterone measurements is satisfactory. However, the comparability between laboratories using different measurement systems remains lacking, indicating the long way to achieve standardization and harmonization for these two analytes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2024-0373","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:26:20Z","timestamp":1714476380000},"page":"2233-2241","source":"Crossref","is-referenced-by-count":5,"title":["Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China"],"prefix":"10.1515","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4174-6047","authenticated-orcid":false,"given":"Weiyan","family":"Zhou","sequence":"first","affiliation":[{"name":"12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital\/ National Center of Gerontology , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-0267","authenticated-orcid":false,"given":"Yuhang","family":"Deng","sequence":"additional","affiliation":[{"name":"12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital\/ National Center of Gerontology , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Ma","sequence":"additional","affiliation":[{"name":"National Center for Cardiovascular Diseases & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Zhao","sequence":"additional","affiliation":[{"name":"12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital\/ National Center of Gerontology , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7105-8563","authenticated-orcid":false,"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for Cardiovascular Diseases & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory , Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , West China Hospital, Sichuan University , Chengdu , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital\/ National Center of Gerontology , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital, Capital Medical University , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-7511","authenticated-orcid":false,"given":"Chuanbao","family":"Zhang","sequence":"additional","affiliation":[{"name":"12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital\/ National Center of Gerontology , Beijing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"2026051214021121315_j_cclm-2024-0373_ref_001","doi-asserted-by":"crossref","unstructured":"Yin, R, Yin, L, Li, L, Silva-Nash, J, Tan, J, Pan, Z, et al.. Hypertension in China: burdens, guidelines and policy responses: a state-of-the-art review. J Hum Hypertens 2022;36:126\u201334. https:\/\/doi.org\/10.1038\/s41371-021-00570-z.","DOI":"10.1038\/s41371-021-00570-z"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_002","doi-asserted-by":"crossref","unstructured":"Funder, JW, Carey, RM, Mantero, F, Murad, MH, Reincke, M, Shibata, H, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889\u2013916. https:\/\/doi.org\/10.1210\/jc.2015-4061.","DOI":"10.1210\/jc.2015-4061"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_003","doi-asserted-by":"crossref","unstructured":"Monticone, S, Burrello, J, Tizzani, D, Bertello, C, Viola, A, Buffolo, F, et al.. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052.","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_004","doi-asserted-by":"crossref","unstructured":"Funder, JW. Primary aldosteronism: present and future. Vitam Horm 2019;109:285\u2013302. https:\/\/doi.org\/10.1016\/bs.vh.2018.10.006.","DOI":"10.1016\/bs.vh.2018.10.006"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_005","doi-asserted-by":"crossref","unstructured":"Monticone, S, D\u2019Ascenzo, F, Moretti, C, Williams, TA, Veglio, F, Gaita, F, et al.. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic\u00a0review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41\u201350. https:\/\/doi.org\/10.1016\/s2213-8587(17)30319-4.","DOI":"10.1016\/S2213-8587(17)30319-4"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_006","doi-asserted-by":"crossref","unstructured":"Hundemer, GL, Curhan, GC, Yozamp, N, Wang, M, Vaidya, A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018;6:51\u20139. https:\/\/doi.org\/10.1016\/s2213-8587(17)30367-4.","DOI":"10.1016\/S2213-8587(17)30367-4"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_007","doi-asserted-by":"crossref","unstructured":"Murata, M, Kitamura, T, Tamada, D, Mukai, K, Kurebayashi, S, Yamamoto, T, et al.. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens 2017;35:1079\u201385. https:\/\/doi.org\/10.1097\/hjh.0000000000001251.","DOI":"10.1097\/HJH.0000000000001251"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_008","doi-asserted-by":"crossref","unstructured":"Young, WJ. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019;285:126\u201348. https:\/\/doi.org\/10.1111\/joim.12831.","DOI":"10.1111\/joim.12831"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_009","doi-asserted-by":"crossref","unstructured":"Martin, RS, Hayslett, JP. Role of aldosterone in the mechanism of renal potassium adaptation. Pflugers Arch 1986;407:76\u201381. https:\/\/doi.org\/10.1007\/bf00580724.","DOI":"10.1007\/BF00580724"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_010","doi-asserted-by":"crossref","unstructured":"Vetter, H, Vetter, W. Regulation of aldosterone secretion in primary aldosteronism. Horm Metab Res 1975;7:418\u201324. https:\/\/doi.org\/10.1055\/s-0028-1093697.","DOI":"10.1055\/s-0028-1093697"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_011","doi-asserted-by":"crossref","unstructured":"Giacchetti, G, Opocher, G, Sarzani, R, Rappelli, A, Mantero, F. Angiotensin II and the adrenal. Clin Exp Pharmacol Physiol 1996;23:S119\u201324. https:\/\/doi.org\/10.1111\/j.1440-1681.1996.tb03072.x.","DOI":"10.1111\/j.1440-1681.1996.tb03072.x"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_012","doi-asserted-by":"crossref","unstructured":"Gordon, RD. Primary aldosteronism. J Endocrinol Invest 1995;18:495\u2013511. https:\/\/doi.org\/10.1007\/bf03349761.","DOI":"10.1007\/BF03349761"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_013","doi-asserted-by":"crossref","unstructured":"Turcu, AF, Yang, J, Vaidya, A. Primary aldosteronism\u00a0\u2013 a multidimensional syndrome. Nat Rev Endocrinol 2022;18:665\u201382. https:\/\/doi.org\/10.1038\/s41574-022-00730-2.","DOI":"10.1038\/s41574-022-00730-2"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_014","doi-asserted-by":"crossref","unstructured":"Reincke, M, Bancos, I, Mulatero, P, Scholl, UI, Stowasser, M, Williams, TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021;9:876\u201392. https:\/\/doi.org\/10.1016\/s2213-8587(21)00210-2.","DOI":"10.1016\/S2213-8587(21)00210-2"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_015","doi-asserted-by":"crossref","unstructured":"Coulon, C, Lotierzo, M, Fesler, P, Roubille, C, Badiou, S, Dupuy, AM, et al.. Analytical evaluation and bioclinical validation of new aldosterone and renin immunoassays. Clin Chem Lab Med 2022;60:1763\u201371. https:\/\/doi.org\/10.1515\/cclm-2022-0576.","DOI":"10.1515\/cclm-2022-0576"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_016","doi-asserted-by":"crossref","unstructured":"Giangrande, C, Vaneeckhoutte, H, Boeuf, A, Lalere, B, Hirtz, C, Lehmann, S, et al.. Development of a candidate reference measurement procedure by ID-LC-MS\/MS for total tau protein measurement in cerebrospinal fluid (CSF). Clin Chem Lab Med 2023;61:1235\u201344. https:\/\/doi.org\/10.1515\/cclm-2022-1250.","DOI":"10.1515\/cclm-2022-1250"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_017","doi-asserted-by":"crossref","unstructured":"Taibon, J, Santner, T, Singh, N, Ibrahim, SC, Babitzki, G, K\u00f6ppl, D, et al.. An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS\/MS)-based candidate reference measurement procedure (RMP) for the quantification of aldosterone in human serum and plasma. Clin Chem Lab Med 2023;61:1902\u201316. https:\/\/doi.org\/10.1515\/cclm-2022-0996.","DOI":"10.1515\/cclm-2022-0996"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_018","doi-asserted-by":"crossref","unstructured":"St\u00f6ckl, D, Reinauer, H, Thienpont, LM, De Leenheer, AP. Determination of aldosterone in human serum by isotope dilution gas chromatography\/mass spectrometry using a new heptafluorobutyryl derivative. Biol Mass Spectrom 1991;20:657\u201364. https:\/\/doi.org\/10.1002\/bms.1200201102.","DOI":"10.1002\/bms.1200201102"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_019","doi-asserted-by":"crossref","unstructured":"Juutilainen, A, Savolainen, K, Romppanen, J, Turpeinen, U, H\u00e4m\u00e4l\u00e4inen, E, Kemppainen, J, et al.. Combination of LC-MS\/MS aldosterone and automated direct renin in screening for primary aldosteronism. Clin Chim Acta 2014;433:209\u201315. https:\/\/doi.org\/10.1016\/j.cca.2014.03.015.","DOI":"10.1016\/j.cca.2014.03.015"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_020","doi-asserted-by":"crossref","unstructured":"Deng, Y, Zhang, C, Wang, J, Zeng, J, Zhang, J, Zhang, T, et al.. An accurate isotope dilution liquid chromatography-tandem mass spectrometry method for serum C-peptide and its use in harmonization in China. Ann Lab Med 2023;43:345\u201354. https:\/\/doi.org\/10.3343\/alm.2023.43.4.345.","DOI":"10.3343\/alm.2023.43.4.345"},{"key":"2026051214021121315_j_cclm-2024-0373_ref_021","doi-asserted-by":"crossref","unstructured":"Little, RR, Wielgosz, RI, Josephs, R, Kinumi, T, Takatsu, A, Li, H, et al.. Implementing a reference measurement system for C-peptide: successes and lessons learned. Clin Chem 2017;63:1447\u201356. https:\/\/doi.org\/10.1373\/clinchem.2016.269274.","DOI":"10.1373\/clinchem.2016.269274"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-0373\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-0373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:09:50Z","timestamp":1778594990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-0373\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,3,29]]},"published-print":{"date-parts":[[2024,10,28]]}},"alternative-id":["10.1515\/cclm-2024-0373"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-0373","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}